dc.contributor.author |
Larsen, R.A. |
|
dc.contributor.author |
Bauer, M. |
|
dc.contributor.author |
Pitisuttithum, P. |
|
dc.contributor.author |
Sanchez, A. |
|
dc.contributor.author |
Tansuphaswadikul, S. |
|
dc.contributor.author |
Wuthiekanun, V. |
|
dc.contributor.author |
Peacock, S.J. |
|
dc.contributor.author |
Simpson, A.J.H. |
|
dc.contributor.author |
Fothergill, A.W. |
|
dc.contributor.author |
Rinaldi, M.G. |
|
dc.contributor.author |
Bustamante Rufino, Ana Beatriz |
|
dc.contributor.author |
Thomas, A.M. |
|
dc.contributor.author |
Altomstone, R. |
|
dc.contributor.author |
Day, N.P.J. |
|
dc.contributor.author |
White, N.J. |
|
dc.date.accessioned |
2022-01-18T19:26:53Z |
|
dc.date.available |
2022-01-18T19:26:53Z |
|
dc.date.issued |
2011 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/10990 |
|
dc.description.abstract |
Testing of Cryptococcus neoformans for susceptibility to antifungal drugs by standard microtiter methods has not been shown to correlate with clinical outcomes. This report describes a modified quantitative broth macrodilution susceptibility method showing a correlation with both the patient's quantitative biological response in the cerebrospinal fluid (CSF) and the survival of 85 patients treated with amphotericin B (AMB). The Spearman rank correlation between the quantitative in vitro measure of susceptibility and the quantitative measure of the number of organisms in the patient's CSF was 0.37 (P < 0.01; 95% confidence interval [95% CI], 0.20, 0.60) for the first susceptibility test replicate and 0.46 (P < 0.001; 95% CI, 0.21, 0.62) for the second susceptibility test replicate. The median in vitro estimated response (defined as the fungal burden after AMB treatment) at 1.5 mg/liter AMB for patients alive at day 14 was 5 CFU (95% CI, 3, 8), compared to 57 CFU (95% CI, 4, 832) for those who died before day 14. These exploratory results suggest that patients whose isolates show a quantitative in vitro susceptibility response below 10 CFU/ml were more likely to survive beyond day 14. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
American Society for Microbiology |
|
dc.relation.ispartofseries |
Antimicrobial Agents and Chemotherapy |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Humans |
en_US |
dc.subject |
article |
en_US |
dc.subject |
controlled study |
en_US |
dc.subject |
major clinical study |
en_US |
dc.subject |
in vitro study |
en_US |
dc.subject |
priority journal |
en_US |
dc.subject |
quantitative analysis |
en_US |
dc.subject |
Treatment Outcome |
en_US |
dc.subject |
Survival Rate |
en_US |
dc.subject |
AIDS-Related Opportunistic Infections |
en_US |
dc.subject |
Microbial Sensitivity Tests |
en_US |
dc.subject |
cerebrospinal fluid |
en_US |
dc.subject |
broth dilution |
en_US |
dc.subject |
Antifungal Agents |
en_US |
dc.subject |
antifungal susceptibility |
en_US |
dc.subject |
Amphotericin B |
en_US |
dc.subject |
Cerebrospinal Fluid |
en_US |
dc.subject |
Colony Count, Microbial |
en_US |
dc.subject |
colony forming unit |
en_US |
dc.subject |
correlation coefficient |
en_US |
dc.subject |
Cryptococcus neoformans |
en_US |
dc.subject |
Meningitis, Cryptococcal |
en_US |
dc.subject |
survival |
en_US |
dc.title |
Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1128/AAC.00034-11 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.02.21 |
|
dc.relation.issn |
1098-6596 |
|